YDES

YD Bio Limited Ordinary Shares

YDES

Market cap $1.15B

Overview Fund Activity

16.39 USD

+0.84

5.4%

At close Updated Sep 10, 4:00 PM EDT

Pre-market

After hours

15.95

-0.44

2.68%

1 day

5.4%

5 days

3.34%

1 month

31.12%

3 months

31.12%

6 months

31.12%

Year to date

31.12%

1 year

31.12%

5 years

31.12%

10 years

31.12%

About: YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

Healthcare Biotechnology

–

Funds holding %

of 7,460 funds

–

Analysts bullish %

Financial journalist opinion

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market Expansion Trading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Nasdaq Global Market on August 29, 2025, under the ticker symbols "YDES" and "YDESW" NEW YORK , Aug. 29, 2025 /PRNewswire/ -- YD Bio Limited ("YD Bio Ltd" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of its previously announced business combination with Breeze Holdings Acquisition Corp. ("Breeze"), a publicly traded special purpose acquisition company. Beginning August 29, 2025, YD Bio's ordinary shares and warrants will trade on Nasdaq Global Market under the ticker symbols "YDES" and "YDESW," respectively.

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

TAIWAN, Aug. 28, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of its previously announced business combination with Breeze Holdings Acquisition Corp. (“Breeze”), a publicly traded special purpose acquisition company. Beginning August 29, 2025, YD Bio's ordinary shares and warrants will trade on Nasdaq Global Market under the ticker symbols “YDES” and “YDESW,” respectively. The transaction was approved by Breeze shareholders at an extraordinary general meeting held on August 14, 2025.

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

See News Rankings

Charts implemented using Lightweight Charts™